Establishment of a Chinese street rabies virus library and its application for detecting neutralizing activity

Peng-Cheng Yu, Xiao-Yan Tao, Li-Hua Wang, Qing Tang, Li-Yun Fan, Shu-Xia Zhang, Shu-Qing Liu, Xue-Xin Lu, Gui-Zhen Wu* and Wu-Yang Zhu*

Abstract

Background: The injection of rabies immune globulin (RIG) is of the utmost importance in the management of category III exposures to rabies-suspect animals. Because of the high cost and limited availability of existing RIG, one possible replacement for RIG is monoclonal antibodies (MAbs) against the rabies virus (RABV). Consequently, it is necessary to determine the neutralizing activity of the MAbs against rabies viruses, especially street rabies virus. However, the method to detect the neutralizing activity of MAbs against street rabies virus remains undefined.

Methods: To establish a method for detecting the neutralizing activity of MAbs against street rabies virus, we constructed a library consisting of 12 strains of street RABV from 11 provinces in China. Using this street RABV library and the Reed–Muench formula, we established a method for detecting the neutralizing titer of the MAbs. The reliability and repeatability of the method were evaluated by repeatedly measuring the neutralizing activity of a MAb and a post vaccination serum.

Results: A total of 12 strains of street RABV were chosen for inclusion in the street RABV library, which covered six Chinese lineages (China I–China VI) and grew to high titers in N2A cells (> 10^5 FFD50/ml). On the basis of the library, we constructed the method to detect the neutralizing activity of the MAbs. The results of repeatedly measuring the MAbs and positive serum showed excellent reliability and repeatability of the method established in this study.

Conclusions: This study established a street RABV library reflecting the epidemiological features of Chinese rabies viruses, which provides a platform for detecting the neutralizing activity of MAbs against rabies viruses circulating in China.

Keywords: Street RABV, MAbs, Neutralizing activity

Background

Rabies is a fatal disease that is preventable when post exposure prophylaxis (PEP) is administered in a timely fashion. However, approximately 59,000 humans die from rabies each year [1]. The World Health Organization (WHO) recommends that prophylaxis for the prevention of disease in humans exposed to the rabies virus (RABV), which is a negative-sense single-stranded RNA (ssRNA) virus from the genus Lyssavirus, family Rhabdoviridae, should include prompt and thorough wound cleansing followed by passive vaccination with rabies immune globulin (RIG) and vaccination with the rabies vaccine. The report of the WHO/Bill and Melinda Gates Foundation Consultation agreed that the injection of rabies immune globulin into or around wounds is of the utmost importance in the management of category III exposures, which include single or multiple transdermal bites or scratches, licks on broken skin, contamination of mucous membranes with saliva from licks and exposure to bats.
Rabies immunoglobulin neutralizes the rabies virus at the wound site during the period before the immune system responds to the vaccine via the production of RABV-neutralizing antibodies. Both active and passive immunization prevent the RABV from infiltrating the central nervous system but become ineffective once the virus has entered the central nervous system. Currently available rabies PEP for use in humans includes human rabies immune globulin (HRIG) and equine rabies immune globulin (ERIG). Treatment failures have occurred when RIG is delayed and not injected into the wound, if some deviation is made from the recommended PEP protocol, or when less than the recommended amount of RIG is administered \[2, 3\]. In addition, unpurified equine antirabies serum may still be used in some countries because of the shortage and high cost of HRIG and ERIG. The use of this antirabies serum is associated with higher rates of serious adverse reactions, including anaphylaxis \[4\]. Thus, because of the high costs and limited availability of existing RIGs, the WHO strongly recommends their replacement with a product that is at least equally potent and safer \[5\].

One possible replacement for RIG is monoclonal antibodies (MAbs) against the rabies virus. However, it is necessary to determine the neutralizing activity of each MAb against rabies viruses, especially street rabies virus, and compare it with that of HRIG. In our study, we constructed a library of Chinese street RABV strains including RABVs from different provinces, different hosts and different lineages, which was used to evaluate the neutralizing activity of MAbs against different street RABVs.

**Methods**

**Street RABV, HRIG, neuro-2a cells, MAbs and serum**

Table 1 lists the 24 strains of the rabies virus from 14 different provinces that were selected to establish the Chinese street RABV library. This library included street RABVs from four different hosts, including six samples from human brain tissue, two from cow brain tissue, one from ferret-badger brain tissue, and 15 from canine brain tissue.

The national reference standard HRIG (30 IU/ml) was purchased from the National Institute for Biological Standards and Control (Potters Bar, Herts, UK). The rabies direct fluorescent antibody (DFA) reagent (fluorescein isothiocyanate-conjugated antirabies nucleoprotein antibody) was purchased from Fujirebio Diagnostics, Inc. (Malvern, PA, US). The mouse neuroblast cell line Neuro-2a (CCL-131, obtained from the American Type Culture Collection, Manassas, VA, US), was used for the routine diagnosis of rabies. BSR cells (a cloned baby hamster kidney cell line) were cultured at 37 °C in a 5% CO₂ humidified incubator and maintained in Dulbecco’s minimum essential medium (Gibco, Waltham, MA, USA). The standard challenge virus (CVS-11) was provided by the National Institutes for Food and Drug Control, China. TRN006, a human MAb against the rabies virus, which has been patented (CN201310007039.1), was supplied by Tsinghua University. Post vaccination serum used to investigate the repeatability was stored in our lab.

**Phylogenetic analysis of the 24 RABV strains**

The glycoprotein gene of the 24 RABV strains was already sequenced by our lab \[6, 7\], and based on the complete G gene sequences of these strains and other representative strains from China, a phylogenetic tree was constructed using MEGA 7 software with the neighbor-joining (NJ) method and 1 000 bootstrap replicates \[8\].

| Code      | Host   | Province     | Code      | Host   | Province     |
|-----------|--------|--------------|-----------|--------|--------------|
| CHN0610H  | Human  | Hunan        | CNX8601   | Human  | Ningxia      |
| CHN0633D  | Dog    | Hunan        | CNX8511   | Human  | Ningxia      |
| CHN0635H  | Human  | Hunan        | GDZQ45    | Dog    | Guangdong    |
| CYN1009D  | Dog    | Yunnan       | GDZQ46    | Dog    | Guangdong    |
| CYN1003C  | Cow    | Yunnan       | CSC1015D  | Dog    | Sichuan      |
| CYN1025H  | Human  | Yunnan       | CSC1016D  | Dog    | Sichuan      |
| CJS0903D  | Dog    | Jiangxi      | CSX0904D  | Dog    | Shanxi       |
| CJS0621D  | Dog    | Jiangsu      | CSX0901D  | Dog    | Shanxi       |
| CJS0840H  | Human  | Jiangsu      | GuangxiCx14 | Dog    | Guangxi      |
| CJS0847D  | Dog    | Jiangsu      | CAH0501D  | Dog    | Anhui        |
| CSD0710D  | Dog    | Shandong     | D19       | Ferret | Zhejiang     |
| CQH1202D  | Cow    | Inner Mongolia | CNM1103C | Dog    | Qinghai      |
Titration of street RABV

All brain tissue suspensions (w/v = 30%) were homogenized in Modified Eagle Medium (MEM) (Sigma-Aldrich, St. Louis, MO, US) and then serially diluted 10-fold from $10^{-12}$ to $10^{-8}$ in MEM containing 10% fetal bovine serum (Gibco, Waltham, MA, US). Then, 100 µl of each dilution of the virus suspension was transferred into six replicate wells of a 96-well plate and incubated at 37 °C for 1 h. Next, 100 µl Neuro-2a cell suspension ($5 \times 10^5$ cells/ml) was added to each well, and the plates were incubated at 37 °C in 5% CO$_2$ for 48 h. The DFA test was then performed to enumerate the foci of infection from street RABV and to calculate the titer of street RABV (50% fluorescent focus-forming dose per ml; FFD$_{50}$/ml).

DFA test

The 96-well plates were fixed in cold acetone, incubated with 50 µl/well of rabies DFA reagent at 37 °C for 30 min, then washed three times using 100 µl of phosphate-buffered saline (PBS)/well, sealed with 90% glycerol, and viewed using fluorescence microscopy.

Neutralization assay

MAbs and HRIG were diluted from $10^{-1}$ to $10^{-6}$ in MEM-10 (MEM containing 10% FBS); 100 µl of a mixture of MAb and HRIG was transferred to six replicate wells of the 96-well plate; PBS was added to another six replicate wells, and another six replicate wells were used as a cell-only control. Then, 100 µl of the challenge street RABV at a titer of 50 FFD$_{50}$/100 µl was added to the wells and mixed. The street RABV back titration was also performed by adding 100 µl of 50 FFD$_{50}$/100 µl, 5 FFD$_{50}$/100 µl, and 0.5 FFD$_{50}$/100 µl viruses each to the six replicate wells. The plates were then incubated at 37 °C for 60 min to allow neutralization of the virus before 100 µl Neuro-2a cells at a concentration of $5 \times 10^5$ cells/ml was added to all wells. The plate was incubated at 37 °C in 5% CO$_2$ for 48 h, and then a DFA assay was performed to enumerate the infection foci.

Rapid fluorescent focus inhibition test

The challenge virus standard (CVS-11) at the dose that caused 80% infection of BSR cells after 24 h was incubated with serial dilutions of the sera to be titrated. A reference serum (30 IU/ml) was included in each test. After 1 h of incubation at 37 °C, BSR cells were added to each well. After 24 h of incubation at 37 °C in 5% CO$_2$, the percentage of infected cells at each serum dilution was estimated. This allowed the determination of the titer of the unknown neutralizing antibodies compared with that of the reference serum. The titer of the neutralizing antibodies in the sera was recorded as IU/ml, which is the global standard. Serum with a neutralizing antibody titer $\geq$0.5 IU/ml was considered positive.

Data analysis

Statistical analysis and graphing were performed using the commercially available software GraphPad Prism 5.0 (GraphPad Software, CA, US) and Microsoft Office Excel 2007 (Microsoft Corp., Redmond, WA, US). Specifically, the intraclass correlation coefficient (ICC) and standard deviation (SD) were used to evaluate the repeatability and reliability of the method.

Results

Titration of street RABV

Twenty-four strains of street RABV were titrated in Neuro-2a cells, and 12 street RABV strains from 11 provinces, which showed the better multiplication capacity ($>10^5$ FFD$_{50}$/ml, Table 2), were chosen for inclusion in the street RABV library to be used to detect the neutralizing activity of rabies virus-specific MAbs.

Phylogenetic characteristics of the Chinese street RABVs

Glycoprotein genes of 44 Chinese street RABV strains were used to construct a phylogenetic tree (Fig. 1). Of these strains, 16 belonged to the China I lineage, nine to the China II lineage, seven to the China III lineage, four to the China IV lineage, five to the China V lineage and three to the China VI lineage. The 12 strains included in the street RABV library were distributed over six lineages as follows: six strains from six different provinces belonged to the China I lineage, two strains to the China V lineage, and one strain each to the China II, China III, China IV, and China VI lineages.

Table 2 Classification and titers of the strains included in the street RABV library

| Code    | Titer (FFD$_{50}$/ml) | Host  | Province     |
|---------|----------------------|-------|--------------|
| CAH0501D| $3 \times 10^4$      | Dog   | Anhui        |
| CJS0621D| $6 \times 10^6$      | Dog   | Jiangsu      |
| CSC1016D| $5 \times 10^7$      | Dog   | Sichuan      |
| CJX0903D| $4 \times 10^6$      | Dog   | Jiangxi      |
| CHN0610H| $1 \times 10^5$      | Human | Hunan        |
| CSX0904D| $4 \times 10^7$      | Dog   | Shanxi       |
| CNX8601 | $3 \times 10^5$      | Human | Ningxia      |
| CNX8511 | $5 \times 10^7$      | Human | Ningxia      |
| CYN1009D| $2 \times 10^6$      | Cow   | Yunnan       |
| GDZQ45  | $7 \times 10^5$      | Dog   | Guangdong    |
| CNM1103C| $4 \times 10^8$      | Cow   | Inner Mongolia|
| CQH1202D| $3 \times 10^7$      | Dog   | Qinghai      |
Interpretation and determination of the MAb titers against street RABVs

In the test system, the cell control wells should contain no infected cells, while the PBS positive control wells have the maximum number of foci. For the back titration of street RABV strains, the six wells containing the challenge virus dose should all be positive; the acceptable range for positive wells at the $10^{-1}$ dilution was 4–6 wells and that at the $10^{-2}$ dilution was 0–3 wells.

The percentage of wells containing infected cells at each dilution was calculated, and the Reed–Muench method was then used to calculate the difference between the logarithm of the starting dilution and the logarithm of the 50% endpoint dilution (difference of the logarithms) using the following formula:

$$\frac{50\% - \text{(infectivity next below 50\%)} }{\text{(infectivity next above 50\%)} - \text{(infectivity next below 50\%)} } \times \log_{10} \text{dilution factor}$$

Because the infectivity increases as the dilution increases, the 50% endpoint dilution is higher than the starting dilution.

Fig. 1 NJ phylogenetic tree of all the Chinese street RABVs classified according to the glycoprotein gene sequences. These isolates can be divided into six lineages (CHINA I–VI), which are distinguished by the different colored branches. The red triangles indicate the strains chosen for inclusion in the street RABV library. Taxa are given in the format (GenBank Accession No./strain) RABV: Rabies virus.
Finally, the relative potency of the MAb (IU/ml) was calculated using the following equation:

\[
\frac{50\%\text{ endpoint dilution of MAb against street RABV}}{50\%\text{ endpoint dilution of HRIG against street RABV}} \times \text{titer of HRIG}
\]

Repeatability of the method established for detecting the MAb neutralizing activity

Five replicate experiments were performed on different days to assess the repeatability and reliability of the method (Fig. 2a). Three strains of street RABVs from the library, namely, CNX8511, CSX0904D, and CSC1016D, were chosen as the challenge viruses. CNX8511 is from the China V lineage, and CSX0904D and CSC1016D are from the China I lineage. The results were analyzed using the ICC (Intraclass Correlation Coefficient) and showed that the ICC values were all > 0.92, which indicates excellent reliability.

The rapid fluorescent focus inhibition test (RFFIT) is a WHO standard assay for determining the neutralizing activity of the rabies virus in serum, which is mostly used to evaluate the immunity effect after vaccination against rabies. To compare the reliability of the method with that of RFFIT, RFFIT titers of a postvaccination serum sample were used as a control to compare with those derived from the method established in this study. In the experiment, GDZQ45, CNM1103C, CQH1202D and CYN1009D, which belonged to the China II, China III, China IV and China VI lineages, respectively, were used to determine the titers of the positive serum. The SD values of the titers obtained from the four strains of street rabies viruses were all ≤0.66, which were comparable with that of RFFIT (0.63) (Fig. 2b), suggesting no significant difference between the repeatability of the two methods. Together, the repeated measuring of the

![Fig. 2](image-url) Repeatability test of the method. a Five replicate experiments were performed using the method, and CNX8511, CSX0904D, and CSC1016D were used as the challenge viruses. b Postvaccination serum was detected 5 times using RFFIT and the method that we established. GDZQ45, CNM1103C, CQH1202D and CYN1009D were used as the challenge viruses.
MAb or the positive serum showed the excellent reliability and stability of the method established in this study.

**Discussion**

Because the WHO has strongly encouraged the development of a replacement for HRIG [5], mouse and human MAb products against the rabies virus have recently been generated. Two products are in advanced clinical trials, namely, CL184 (produced by Crucell and based on the combination of two antibodies called CR57 and CR4098) and RMAb (produced by MassBiologics and the Serum Institute of India and based on a single MAb). Moreover, these MAb products have the advantages of high specificity, high affinity, and low price, and they are easier to manufacture than the current immune globulin therapy [9–13]. Cocktails of the MAb are promising; for instance, a combination of monoclonal antibodies (ZMapp) optimized from two previous antibody cocktails was able to rescue 100% of rhesus macaques when treatment was initiated up to 5 days post challenge [14]. An important requirement for MAb is that they confer similar rabies virus-neutralizing activity to that of HRIG. In the selection and development of a safe and effective MAb-based PEP for rabies virus infections, it is of paramount importance to identify MAb that are able to neutralize street RABVs from all lineages.

As part of the Chinese national surveillance program from 2004 to 2015, more than 7919 specimens of dog brain, cow brain, human brain or saliva, and ferret-badger (Melogale moschata) brain were collected in 15 provinces/municipality/autonomous region(s) (Hunan, Guangxi, Guizhou, Jiangsu, Zhejiang, Shandong, Shanghai, Anhui, Shaanxi, Jiangxi, Sichuan, Guangdong, Qinghai, Inner Mongolia, and Yunnan) and tested for the presence of the rabies virus using the DFA test [15]. During this surveillance, more than 300 rabies virus-positive samples were collected from 23 provinces in China. Current reports indicate that there are now six lineages of street RABV in China [6, 7]. China I, II, V, and VI are sublineages of the Asian clade, China III corresponds to the Cosmopolitan clade, and China IV corresponds to the Arctic-like clade. In this study, 12 strains of street RABV with the highest titers were selected to establish a street RABV library, which covered 11 different provinces of China and six Chinese lineages (China I–VI) [16], and included six China I strains from six different provinces, two China V strains from Ningxia Province, and one strain each of China II, China III, China IV, and China VI.

This library of street RABVs can be used to evaluate the spectrum of reactivity and neutralizing capacity of any antirabies MAb, either from China or from other countries. Moreover, the method can not only detect the neutralization activity of MAb but also detect their titer. In addition to Mab, we also compared the reliability of the method compared with that of RFFIT. The results of our analysis showed that the method had good repeatability. Although some pseudotype virus neutralization tests have been established to test the spectrum of activity of Lyssavirus-neutralizing antibodies, these tests have the limitation that the propagation-competent viruses are easy to mutate, so the eventual evolution of resistant viruses cannot be ruled out [17]. The street RABVs used in our study are street rabies viruses that maintained their original characteristics, with the result that the neutralization assay used in our street RABV library is more stable than the assays that use pseudotype viruses.

More and more street RABV are isolated and identified as we work, we will continue to improve the library to increase the number of the street RABV library and the host, district and lineage coverage, which can be applied to the detection of neutralizing activity of MAb and so on.

**Conclusion**

In this study, we established a method for detecting the neutralizing activity of monoclonal antibodies against street rabies virus. A rabies virus library consisting of 12 strains of street RABV from 11 different provinces of China, which included six Chinese lineages (China I–China VI) and grew to high titers in N2A, was built. This study established a street RABV library reflecting the epidemiological features of Chinese rabies viruses that provides a platform for detecting the neutralizing activity of MAb against rabies viruses.

**Additional file**

**Additional file 1**: Multilingual abstracts in the five official working languages of the United Nations. (PDF 236 kb)

**Abbreviations**

DFA: Direct fluorescent antibody; ERIG: Equine rabies immune globulin; HRIG: Human rabies immune globulin; ICC: Intraclass correlation coefficient; MAb: Monoclonal antibodies; MEM: Minimum essential medium; PBS: Phosphate-buffered saline; PEP: Postexposure prophylaxis; RABV: Rabies virus; RFFIT: Rapid fluorescent focus inhibition test; RIG: Rabies immune globulin; WHO: World Health Organization

**Acknowledgments**

The authors are grateful to their colleagues from the CDCs of the different provinces of China for their help in the sample collection and communication.

**Funding**

This work was supported by the National Program on Key Research Project of China (No. 2016YFDB0500400); the National Natural Science Foundation of China (No. 31500152) and the China Mega-Project for Infectious Disease (No. 2017ZX10104001-004-001).

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article.
Authors’ contributions
P-CY performed the experiments, analyzed the data and wrote the paper. X-YT and L-HW participated in the animal experiments. QT, L-YF, S-XZ, S-QL and X-XL participated in the design of the study and data analysis. All authors read and approved the final manuscript. G-ZW and W-YZ designed the study and participated in the experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethical Committee of the National Institute of Viral Disease Control and Prevention, China CDC.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 10 July 2018 Accepted: 25 October 2018
Published online: 05 December 2018

References
1. Hampson K, Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attian M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9:e0003709.
2. Wilde H, Sirikawin S, Sabcharoen A, Kingmate D, Tantawichien T, Harischandra PA, et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis. 1996;22:228–32.
3. Shill M, Raynes RD, Miller SD. Fatal rabies encephalitis despite appropriate postexposure prophylaxis. A case report. N Engl J Med. 1987;316:1257–8.
4. Wilde H, Choomkasien P, Hemachudha T, Supich C, Chutivongs S. Failure of rabies postexposure treatment in Thailand. Vaccine. 1989;7:49–52.
5. World Health Organization. WHO Consultation on a rabies monoclonal antibody cocktail for rabies post-exposure treatment. 2002.
6. Lang SL, Tao XY, Guo ZY, Tang Q, Li H, Yin CP, et al. Molecular characterization of viral G gene in emerging and re-emerging areas of rabies in China: 2007 to 2011. Virol Sin. 2012;27:194–203.
7. Tao X, Tang Q, Rayner S, Guo ZY, Li H, Lang SL, et al. Molecular phylogenetic analysis indicates lineage displacement occurred in Chinese rabies epidemics between 1949 to 2010. PLoS Negl Trop Dis. 2013;7(7):e2294.
8. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33:1870–4.
9. Sloan SE, Hanlon C, Weldon W, Niezgoda M, Blanton J, Self J, et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 2007;25:2800–10.
10. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgoda M, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol. 2005;79:9062–8.
11. Goudsmith J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, et al. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis. 2006;193:796–801.
12. Nagarajan T, Marissen W, Rupprecht C. Monoclonal antibodies for the prevention of rabies: theory and clinical practice. Antibody Technol J. 2014;4:1–12.
13. De Benedictis P, Minola A, Rota Nodari E, Aiello R, Zecchin B, Salomoni A, et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol Med. 2016;8:407–21.
14. Ou X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53.
15. Tao X, Tang Q, Li H, Mo ZI, Zhanh Z, Wang DM, et al. Molecular epidemiology of rabies in southern People's republic of China. Emerg Infect Dis. 2009;15:1192–8.
16. Meng S, Xu G, Wu X, Lei Y, Yan J, Nadin-Davis SA, et al. Transmission dynamics of rabies in China over the last 40 years: 1969–2009. J Clin Virol. 2010;49:47–52.
17. Moeschler S, Locher S, Conzelmann K, Kramer B, Zimmerman G. Quantification of Lyssavirus-neutralizing antibodies using vesicular stomatitis virus pseudotype particles. Viruses. 2016;8:254.